Oral anticoagulant therapy in atrial fibrillation older patients with previous bleeding

Published: March 9, 2020
Abstract Views: 879
PDF: 539
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


Oral anticoagulant therapy (OAT) with direct oral anticoagulant (DOACs) is the established treatment to reduce thromboembolic risk in patients with atrial fibrillation (AF). Bleeding risk scores are useful to identify and correct factors associated with bleeding risk in AF patients on OAT. However, the clinical scenario is more complex in patients with previous bleeding event, and the decision about whether and when starting or re-starting OAT in these patients remains a contentious issue. Major bleeding is associated with a subsequent increase in both short- and long-term mortality, and even minimal bleeding may have prognostic importance because it frequently leads to disruption of antithrombotic therapy. There is an unmet need for guidance on how to manage antithrombotic therapy after bleeding has occurred. While waiting for observational and randomized data to accrue, this paper offers a perspective on managing antithrombotic therapy after bleeding in older patients with AF.



PlumX Metrics


Download data is not yet available.


How to Cite

Bo, Mario, Francesco Giannecchini, Martina Papurello, and Enrico Brunetti. 2020. “Oral Anticoagulant Therapy in Atrial Fibrillation Older Patients With Previous Bleeding”. Monaldi Archives for Chest Disease 90 (1). https://doi.org/10.4081/monaldi.2020.1252.